Eli Lilly's Retatrutide Doubles Ozempic Weight Loss in Head-to-Head Trial

Eli Lilly's experimental drug retatrutide delivered more than double the weight loss of Novo Nordisk's Ozempic in the first direct comparison of the two treatments, according to new trial data. In the study, patients on retatrutide lost an average of 24.2% of their body weight over 48 weeks, compared with 9.9% for those on Ozempic. Retatrutide, a triple-hormone receptor agonist, targets GLP-1, GIP, and glucagon receptors, while Ozempic acts only on GLP-1. The results position retatrutide as a potential 'King Kong' in the booming obesity drug market, which analysts project could exceed $100 billion by 2030. Eli Lilly is already advancing the drug into Phase 3 trials, with regulatory submission possible as early as 2026. For patients and insurers, the promise of greater efficacy could shift prescribing patterns, though side effects and long-term safety remain under review. As competition intensifies, the race to dominate weight-loss therapeutics is accelerating—and retatrutide may redefine the standard of care.